Dr Celine Cano Professor Jane Endicott Dr Ian Hardcastle Dr Claire Jennings Suzanne Kyle et al. | Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile | 2024 |
|
Dr Elaine Willmore Suzanne Kyle Dr Yan Zhao Huw Thomas Dr Kenneth Rankin et al. | Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index | 2024 |
|
Professor Gareth Veal Professor Steve Wedge Dr Christopher Bacon Professor Philip Sloan Professor Alastair Greystoke et al. | A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer | 2023 |
|
Dr Catherine Salvini Benoit Darlot Jack Davison Dr Mathew Martin Dr Susan Tudhope et al. | Fragment expansion with NUDELs – poised DNA-encoded libraries | 2023 |
|
Duncan Miller Dr Suzannah Harnor Dr Mathew Martin Dr Richard Noble Professor Steve Wedge et al. | Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy | 2023 |
|
Dr Nahoum Anthony Charlotte Jennings Dr Mathew Martin Dr Richard Noble Nicole Phillips et al. | Targeting cytotoxic agents through EGFR-mediated covalent binding and release | 2023 |
|
Duncan Miller Tristan Reuillon Dr Lauren Molyneux Dr Tim Blackburn Dr Noel Edwards et al. | Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor | 2022 |
|
Dr Richard Noble Huw Thomas Dr Yan Zhao Professor Steve Wedge
| Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma | 2022 |
|
Islam Al-Khawaldeh Dr Christine Basmadjian Dr Cinzia Bordoni Dr Suzannah Harnor Amy Heptinstall et al. | An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK) | 2021 |
|
Dr Ian Hardcastle Dr Ruth Bawn Dr Tim Blackburn Dr Celine Cano Dr Sarah Cully et al. | Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction | 2021 |
|
John Moir Anna Long Dr Beate Haugk Jeremy French Richard Charnley et al. | Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer | 2020 |
|
Stephanie Myers Duncan Miller Dr Lauren Molyneux Dr Mercedeh Arasta Dr Ruth Bawn et al. | Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4 | 2019 |
|
Dr Catherine Willoughby Huw Thomas Dr Elaine Willmore Suzanne Kyle Dr Anita Wittner et al. | Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy | 2019 |
|
Professor Ruth Plummer Professor Steve Wedge Professor Gareth Veal
| A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours | 2018 |
|
Honorine Lebraud Dr Richard Noble Nicole Phillips Dr Yan Zhao Professor Herbie Newell et al. | A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition | 2018 |
|
Duncan Miller Dr Mathew Martin Santosh Adhikari Alfie Brennan Professor Jane Endicott et al. | Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach | 2018 |
|
Dr Celine Cano Dr Suzannah Harnor Dr Elaine Willmore Professor Steve Wedge
| Targeting DNA-PK as a Therapeutic Approach in Oncology | 2018 |
|
Professor Steve Wedge
| Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib | 2017 |
|
Professor Steve Wedge
| A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer | 2017 |
|
Lucy Gentles Dr Calum Kirk Huw Thomas Professor Steve Wedge Professor Nicola Curtin et al. | An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer | 2017 |
|
Dr Dominic Jones Professor Martin Noble Professor Steve Wedge Professor Craig Robson Dr Luke Gaughan et al. | Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer | 2017 |
|
Christopher Coxon Dr Suzannah Harnor Dr Mathew Martin Dr Benoit Carbain Emeritus Professor Bernard Golding et al. | Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines | 2017 |
|
Stephen Hallett Dr Martyna Pastok Dr Anita Wittner Professor Steve Wedge Professor Martin Noble et al. | Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System | 2017 |
|
Dr Richard Noble Dr Natalie Bell Dr Helen Blair Huw Thomas Nicole Phillips et al. | Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma | 2017 |
|
Professor Ruth Plummer Professor Steve Wedge
| Clinical development of new drug-radiotherapy combinations | 2016 |
|
Lan Wang Professor Herbie Newell Professor Steve Wedge
| Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation | 2016 |
|
Dominic Jones Dr Mark Wade Jim Grey Dr Sirintra Nakjang Wenrui Guo et al. | Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy | 2015 |
|
Elisa Meschini Dr Regina Mora Vidal Dr Mathew Martin Dr Will Stanley Tristan Reuillon et al. | Identification and characterization of an irreversible inhibitor of CDK2 | 2015 |
|
Professor Steve Wedge
| Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel | 2015 |
|
Dr Natalie Bell Dr Helen Blair Lisa Price Dr Katrina Wood Professor Hermann Josef Vormoor et al. | Patient-derived xenograft and in vivo bioluminescent modelling of B-cell NHL | 2015 |
|
Dr Mathew Martin Elisa Meschini Lan Wang Dr Regina Mora Vidal Tristan Reuillon et al. | Identification and characterization of an irreversible inhibitor of CDK2 | 2014 |
|
Professor Steve Wedge
| Induction of HIF1a influences estrogen receptor expression in ex-vivo culture of tumour tissue | 2014 |
|
Professor Steve Wedge
| Mechanisms that influence tumour response to VEGF-pathway inhibitors | 2014 |
|
Dr Susan Tudhope Dr Yan Zhao Dr Anita Wittner Annalisa Bertoli Santosh Adhikari et al. | Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels | 2014 |
|
Matthew Farren Professor Steve Wedge
| Tumor Stromal Phenotypes Define VEGF Sensitivity-Response | 2014 |
|
Annalisa Bertoli Santosh Adhikari Dr Suzannah Harnor Dr Yan Zhao Professor John Lunec et al. | Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction | 2014 |
|
Professor Steve Wedge
| Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies | 2013 |
|
Sarah Jane Ross Dr Fadhel Shaheen Dr Luke Gaughan Professor Craig Robson Professor Steve Wedge et al. | AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo | 2013 |
|
Professor Steve Wedge
| Tumour-stromal architecture can define the intrinsic tumour response to VEGF-targeted therapy | 2013 |
|
Professor Steve Wedge
| An evaluation of 2-deoxy-2- [18F]fluoro-D-glucose and 3‟-Deoxy-3‟-[18F]-fluorothymidine uptake in human tumor xenograft models | 2012 |
|
Professor Steve Wedge
| Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies | 2012 |
|
Professor Steve Wedge
| Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia | 2012 |
|
Dr Aileen Taylor Professor Steve Wedge
| The Clinical Development of Molecularly Targeted Agents in Combination With Radiation Therapy: A Pharmaceutical Perspective | 2012 |
|
Professor Steve Wedge
| An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2 dependent angiogenesis without affecting ligand binding | 2011 |
|
Professor Steve Wedge
| Assessing the Activity of Cediranib, a VEGFR-2/-3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR-family | 2011 |
|
Professor Steve Wedge
| Inhibition of PARP-1 by Olaparib (AZD2281) Increasesthe Radiosensitivity of a Lung Tumor Xenograft | 2011 |
|
Professor Steve Wedge
| Guidelines for the welfare and use of animals in cancer research | 2010 |
|
Professor Steve Wedge
| Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model | 2010 |
|
Professor Steve Wedge
| Examining the acute effects of cediranib (RECENTINTM, AZD2171) treatment in tumor models: a dynamic contrast enhanced MRI (DCE-MRI) study using gadopentate | 2009 |
|
Dr Celine Roche Professor Steve Wedge Professor Herbie Newell Dr Michael Tilby
| The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2 | 2009 |
|
Professor Steve Wedge
| The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY- 142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts | 2009 |
|
Professor Steve Wedge
| The use and refinement of rodent models in anti-cancer drug discovery: a review | 2009 |
|
Professor Steve Wedge
| Use of a novel Arg-Gly-Asp radioligand, [18F]-AH111585, to determine changes in tumor vascularity after antitumor therapy | 2009 |
|
Professor Steve Wedge
| Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice | 2008 |
|
Professor Steve Wedge
| Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol) | 2008 |
|
Professor Steve Wedge
| Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts | 2008 |
|
Professor Steve Wedge
| Inhibition of vascular endothelial growth factor-A signaling induces hypertension: examining the effect of cediranib (Recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy | 2008 |
|
Professor Steve Wedge
| Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity | 2008 |
|
Professor Steve Wedge
| The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis | 2008 |
|
Professor Steve Wedge
| VEGF receptor tyrosine kinase inhibitors for the treatment of cancer | 2008 |
|
Professor Steve Wedge
| Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts | 2007 |
|
Professor Steve Wedge
| Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model | 2007 |
|
Professor Steve Wedge
| AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis | 2007 |
|
Professor Steve Wedge
| Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit | 2007 |
|
Professor Steve Wedge
| Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase | 2007 |
|
Professor Robert Wilkinson Professor Steve Wedge
| Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors | 2006 |
|
Professor Steve Wedge
| Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer | 2006 |
|
Professor Steve Wedge
| ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model | 2006 |
|
Professor Steve Wedge
| ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity | 2005 |
|
Professor Steve Wedge
| Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach | 2004 |
|
Professor Steve Wedge
| The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma | 2004 |
|
Professor Steve Wedge
| ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity | 2004 |
|
Professor Steve Wedge
| Dynamic Contrast-Enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts | 2003 |
|
Professor Steve Wedge
| Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media | 2003 |
|
Professor Steve Wedge
| Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours | 2003 |
|
Professor Steve Wedge
| Complete structure of an Increasing Capillary Permeability Protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via VEGF receptor signaling | 2002 |
|
Professor Steve Wedge
| Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors | 2002 |
|
Professor Steve Wedge
| ZD1839 (“Iressa‟), a Specific Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Potentiates Radiotherapy in a Human Colorectal Cancer Xenograft Model | 2002 |
|
Professor Steve Wedge
| ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling and Growth of a Wide Range of Tumor Models Following Chronic Oral Administration | 2002 |
|
Professor Steve Wedge
| ZM323881, a novel inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) tyrosine kinase activity blocks VEGF-mediated increases in microvascular permeability in vivo | 2002 |
|
Professor Steve Wedge
| Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors | 1999 |
|
Dr John Lunn Professor Steve Wedge Professor Herbie Newell Professor Alan Calvert
| O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma | 1998 |
|
Professor Steve Wedge Fiona Chapman Gordon Taylor Huw Thomas Professor Alan Boddy et al. | A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid | 1996 |
|
Professor Steve Wedge Gordon Taylor Professor Alan Boddy Professor Alan Calvert Professor Herbie Newell et al. | Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement | 1995 |
|
Professor Steve Wedge Gordon Taylor Professor Herbie Newell
| Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography | 1995 |
|
Professor Herbie Newell Professor Steve Wedge
| Pharmacokinetics of high molecular weight agents | 1993 |
|
Professor Steve Wedge
| Preclinical evaluation of polymer-bound doxorubicin | 1992 |
|